Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH ALL 2021 | Updates on ponatinib plus venetoclax for R/R Ph+ ALL

Nicholas Short • 29 Apr 2021
ESH ALL 2021
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Dexamethasone Ponatinib Venetoclax

Nicholas Short, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares the results of a Phase I/II study (NCT03576547) of combined ponatinib, venetoclax, and dexamethasone in relapsed/refractory (R/R) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Pre-clinical studies have shown synergy of the combination, and Dr Short highlights that the regimen is entirely oral. So far, the results suggest that the chemotherapy-free regimen is safe and shows promising efficacy with durable responses in a heavily pretreated population. This interview took place during the 2021 European School of Hematology (ESH) 2nd Translational Research Conference on Acute Lymphoblastic Leukemia.

Disclosures

Consulting fees from AstraZeneca, NGMBio, Jazz Pharmaceuticals.
Research funding from Takeda Oncology and Astellas Pharma Inc.
Honoraria from Amgen and Novartis.

More from Nicholas Short

Azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML: long-term follow-up
2:31
Azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML: long-term follow-up
Nicholas Short • 6 Dec 2025
What is on the horizon for the treatment of B-cell and T-cell ALL?
1:37
What is on the horizon for the treatment of B-cell and T-cell ALL?
Nicholas Short • 6 Dec 2025
Predictors of outcomes with and without alloSCT after first salvage therapy for R/R B-ALL
2:17
Predictors of outcomes with and without alloSCT after first salvage therapy for R/R B-ALL
Nicholas Short • 6 Dec 2025
Comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL: which method is superior?
2:20
Comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL: which method is superior?
Nicholas Short • 6 Dec 2025

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals